KumarS, et al.Blood alcohol levels after carmustine infusion: clinical implications. Clin Pharmacol Ther2015; 98: 175–180.
2.
JonesA, et al.Ethanol in chemotherapy formulations: effects on neurotoxicity. J Oncol Pharm Pract2017; 23: 295–302.
3.
LeeHChenY. Ethanol-drug interactions in cancer patients: a pharmacokinetic perspective. Drug Metab Rev2020; 52: 45–58.
4.
ValeurKSHertelSALundstrømKE,et al.The cumulative daily tolerance levels of potentially toxic excipients ethanol and propylene glycol are commonly exceeded in neonates and infants. Basic Clin Pharmacol Toxicol2018; 122: 523–530.
5.
MillerR, et al.Ethanol exposure risks in oncology patients with liver disease. Liver Int2016; 36: 1013–1020.
6.
OlivieriJ, et al.A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: an observational study on 1038 patients from Fondazione Italiana Linfomi. Biol Blood Marrow Transplant2018; 24: 1814–1822.
7.
PatelR, et al.Propylene glycol toxicity in chemotherapy: case reports and review. J Clin Oncol2019; 37: e19001.
8.
NguyenT, et al.Renal impairment and propylene glycol accumulation in chemotherapy patients. Nephrol Dial Transplant2021; 36: 695–702.
9.
VigneronJAstierATrittlerR, et al.SFPO And ESOP recommendations for the practical stability of anticancer drugs: an update. Ann Pharm Fr2013; 71: 376–389.
10.
KnollL, et al.Physicochemical stability of carmustine-containing medicinal products after reconstitution and after dilution to ready-to-administer infusion solutions stored refrigerated or at room temperature. Eur J Hosp Pharm2023; 30: 11–16.
